No Data
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $18
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival